<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928978</url>
  </required_header>
  <id_info>
    <org_study_id>H-38855</org_study_id>
    <nct_id>NCT02928978</nct_id>
  </id_info>
  <brief_title>Ruxolitinib for Premalignant Breast Disease</brief_title>
  <acronym>TBCRC 042</acronym>
  <official_title>TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julie Nangia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Breast Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the
      study participants will receive ruxolitinib for approximately 15 days, and the other half
      will receive a placebo (sugar pill) for approximately 15 days. Once study participants have
      completed their ruxolitinib or placebo, participants will undergo surgery to remove the
      premalignant breast tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apoptosis</measure>
    <time_frame>15 days (+/- 5 days)</time_frame>
    <description>The number of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the number of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pSTAT5</measure>
    <time_frame>15 days (+/- 5 days)</time_frame>
    <description>To determine the difference in change in pSTAT5 levels between diagnosis and surgery as a function of ruxolitinib treatment versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ductal Carcinoma In Situ</condition>
  <condition>Atypical Lobular Hyperplasia</condition>
  <condition>Atypical Ductal Hyperplasia</condition>
  <condition>Lobular Carcinoma In Situ</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>ruxolitinib tablet</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Jakafi</other_name>
    <other_name>INCB018424 Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Ruxolitinib)</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a breast biopsy showing ADH (atypical ductal hyperplasia), ALH (atypical lobular
             hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ)
             requiring surgical excision. Microinvasive disease is allowed.

               -  NOTE: Tissue from the diagnostic biopsy must be accessible/available for research
                  correlates (i.e., a tissue block or ~10 unstained slides). Due to the nature of
                  the study, fewer slides may be accepted with prior permission from the Protocol
                  Chair if there is insufficient tissue.

          -  Women and men age 18 and older.

          -  Adequate hematologic and organ function, defined as follows:

               -  Absolute neutrophil count ≥ 1500/mm3

               -  Hemoglobin ≥ 9.0 g/dL

               -  Platelet levels &gt;200 x 109/L

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)

               -  AST/ALT ≤ 2.5 x institutional ULN

               -  Alkaline phosphatase ≤ 5 x institutional ULN

               -  Creatinine clearance &gt; 50 mL/min as calculated by the Cockcroft-Gault method

          -  Willing to not use concomitant strong CYP3A4 inhibitors as this could interfere with
             the metabolism of ruxolitinib (i.e azole antifungals, clarithromycin, conivaptan,
             grapefruit juice, mibefradil, nefazodone, protease inhibitors, telithromycin).

          -  Women of child bearing potential must have a negative pregnancy test prior to starting
             therapy. The effects of ruxolitinib on the developing human fetus are unknown. For
             this reason and because class C agents are potentially teratogenic, women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Participants may not be receiving any other investigational agents within 30 days of
             enrollment.

          -  Participants with current or previous history of invasive breast cancer (current
             microinvasive disease is allowed).

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, end stage renal disease (ESRD), or psychiatric illness/social situations
             that would limit compliance with study requirements.

          -  Pregnant or nursing women are excluded from this study

          -  HIV-positive participants on combination antiretroviral therapy are ineligible because
             of the potential for pharmacokinetic interactions with ruxolitinib. Appropriate
             studies will be undertaken in participants receiving combination antiretroviral
             therapy when indicated.

          -  Prior or current treatment with a JAK inhibitor, for any indication.

          -  Known Hepatitis B or C participants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristen Otte</last_name>
    <phone>713-798-8874</phone>
    <email>clinical-research@breastcenter.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Hill</last_name>
      <phone>205-934-4173</phone>
      <email>shill26@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Parker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zhong</last_name>
      <phone>317-274-5495</phone>
      <email>zhongx@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Pickens</last_name>
      <phone>718-379-6868</phone>
      <email>kpickens@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sheldon Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton</last_name>
      <phone>984-215-4906</phone>
      <email>jennifer_dalton@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Downs-Canner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Ingrid Meszoely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kankana Chava</last_name>
      <phone>713-798-1911</phone>
      <email>kankana.chava@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Nangia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mothaffar Rimawi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Ellis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryam Nemati Shaefee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Kent Osborne, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Breast Care Center</investigator_affiliation>
    <investigator_full_name>Julie Nangia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Premalignant Breast Disease</keyword>
  <keyword>ALH</keyword>
  <keyword>ADH</keyword>
  <keyword>DCIS</keyword>
  <keyword>LCIS</keyword>
  <keyword>Breast Cancer Prevention</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

